Nigeria Tightens Regulations on Indian Pharma Exports, New Standards May Spark Industry Concerns

The Nigerian drug regulator has recently heightened its standards for Indian drug makers exporting to the country, News18 has learnt. Drug makers are now required to adhere to the latest specifications and strictly use raw materials following the updated guidelines.

According to the National Agency for Food and Drug Administration and Control (NAFDAC) — the health regulator of Nigeria — the quality of Active Pharmaceutical Ingredients (APIs) used in finished pharmaceutical products manufacturing directly impacts the “safety, efficacy, quality, regulatory compliance, consistency, supply chain, reputation, and cost-effectiveness of pharmaceutical products”.

APIs or bulk drugs are raw materials used in making medicines. For instance: Paracetamol is the API in Crocin.

Starting January 2024, the Nigerian drug regulatory authority will only accept and review applications for product registration if they are supported by raw materials from approved sources. These approved sources specifically include providers of APIs or finished pharmaceutical products.

In a letter written by the director general of NAFDAC, Mojisola Christianah Adeyeye, sent to the Pharmaceuticals Export Promotion Council of India (Pharmexcil), pharmaceutical companies have been asked to “prioritise” sourcing APIs from “reputable suppliers while adhering to stringent quality control measures to ensure the highest standards in their products”Pharmexcil is an arm of the Ministry of Commerce and Industry which is mandated to oversee and boost pharma exports.

Fallout of previous lapses, new rules may impact exports

According to industry experts, the stringent rules may impact Indian exports negatively.

“Nigerian FDA (NAFDAC) mandates the use of API sourced from qualified or stipulated manufacturing facilities. It is a very rigid requirement aimed at the availability of quality medicines in the local market but likely to adversely affect Indian exports. Nigeria is among our top 10 exporting countries and its place keeps fluctuating between fifth and sixth of the top 10,” said Dr PV Appaji, former director general, Pharmexcil.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!